- Tytuł:
- First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan
- Autorzy:
- Źródło:
- In JTO Clinical and Research Reports September 2022 3(9)
Czasopismo naukowe